Novocure Receives FDA Approval for Second Generation Optune System Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make ...
The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...
Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The ...
Optune Lua, formerly known as NovoTTF-100L, is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) ...
St. Helier, NJ's Novocure ($NVCR) submitted a PMA supplement with the FDA, in hopes of marketing an upgraded version of its noninvasive Optune system to treat ...
SHANGHAI, China and ST. HELIER, Jersey, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: ...
Shares drop sharply in response to a disappointing second-quarter earnings report. So what: The number of active patients using the company's Optune system continues to grow at impressive rates, ...
Shares of Novocure continue to trounce the overall markets return. The performance is justified as the company remains in the early innings of its growth ascendancy. The secret to the stellar gains is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback